药学学报, 2022, 57(1): 64-75
嵇梦, 陈大力, 涂家生*, 孙春萌*. 基于组氨酸的肿瘤靶向药物递送系统研究进展[J]. 药学学报, 2022, 57(1): 64-75.
JI Meng, CHEN Da-li, TU Jia-sheng*, SUN Chun-meng*. Research progress of histidine-based tumor-targeting drug delivery systems[J]. Acta Pharmaceutica Sinica, 2022, 57(1): 64-75.

嵇梦, 陈大力, 涂家生*, 孙春萌*
中国药科大学, 药用辅料及仿创药物研发评价中心, 药学院, 国家药品监督管理局药物制剂及辅料研究与评价重点实验室, 江苏 南京 210009
关键词:    组氨酸      细胞穿膜肽      肿瘤微环境      药物递送系统      药物治疗     
Research progress of histidine-based tumor-targeting drug delivery systems
JI Meng, CHEN Da-li, TU Jia-sheng*, SUN Chun-meng*
NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China
As a basic amino acid, histidine has a pKa close to the acidity of the tumor microenvironment, thus the charge and solubility of histidine are able to vary as the pH changes. Under a neutral environment, histidine is not charged and exhibits hydrophobic properties, while it can be protonated and becomes hydrophilic when exposed to mildly acidic pH, such as tumor microenvironment. Therefore, histidine is widely used in the design of drug delivery systems to target the mildly acidic pH of tumor microenvironment. This article reviews the recent progresses of histidine-based tumor-targeting drug delivery systems, and summarizes the principles on promoting internalization and tuning drug release by taking advantage of histidine. Finally, we point out the common issues on histidine application and illustrate its future prospects.
Key words:    histidine    cell-penetrating peptide    tumor microenvironment    drug delivery system    therapy   
收稿日期: 2021-08-11
DOI: 10.16438/j.0513-4870.2021-1174
基金项目: 国家自然科学基金资助项目(81972894,81673364)
通讯作者: 涂家生,Tel:86-25-83271305,E-mail:jiashengtu@cpu.edu.cn;孙春萌,E-mail:suncmpharm@cpu.edu.cn
Email: jiashengtu@cpu.edu.cn;suncmpharm@cpu.edu.cn
PDF(6166KB) Free
嵇梦  在本刊中的所有文章
陈大力  在本刊中的所有文章
涂家生*  在本刊中的所有文章
孙春萌*  在本刊中的所有文章

[1] Brosnan ME, Brosnan JT. Histidine metabolism and function[J]. J Nutr, 2020, 150:2570S-2575S.
[2] Mugaka BP, Zhang S, Li RQ, et al. One-pot preparation of peptide-doped metal-amino acid framework for general encapsulation and targeted delivery[J]. ACS Appl Mater Interfaces, 2021, 13:11195-11204.
[3] Horch M, Pinto AF, Mroginski MA, et al. Metal-induced histidine deprotonation in biocatalysis? Experimental and theoretical insights into superoxide reductase[J]. RSC Adv, 2014, 4:54091-54095.
[4] Hu C, Gao HL. Advances in tumor microenvironment responsive and regulatory drug delivery system[J]. Acta Pharm Sin (药学学报), 2020, 55:1520-1527.
[5] Park JS, Han TH, Lee KY, et al. N-Acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs:endocytosis, exocytosis and drug release[J]. J Control Release, 2006, 115:37-45.
[6] Ma YY, Li L, Huang HF, et al. Advances of tumor targeting peptides drug delivery system with pH-sensitive activities[J]. Acta Pharm Sin (药学学报), 2016, 51:717-724.
[7] Mo R, Sun Q, Xue J, et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery[J]. Adv Mater, 2012, 24:3659-3665.
[8] Hung CC, Huang WC, Lin YW, et al. Active tumor permeation and uptake of surface charge-switchable theranostic nanoparticles for imaging-guided photothermal/chemo combinatorial therapy[J]. Theranostics, 2016, 6:302-317.
[9] Iwasaki T, Tokuda Y, Kotake A, et al. Cellular uptake and in vivo distribution of polyhistidine peptides[J]. J Control Release, 2015, 210:115-124.
[10] Hayashi T, Shinagawa M, Kawano T, et al. Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome[J]. Biochem Biophys Res Commun, 2018, 501:648-653.
[11] Zhang W, Song J, Zhang B, et al. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells[J]. Bioconjug Chem, 2011, 22:1410-1415.
[12] Zhang Q, Tang J, Fu L, et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system[J]. Biomaterials, 2013, 34:7980-7993.
[13] Tang B, Zaro JL, Shen Y, et al. Acid-sensitive hybrid polymeric micelles containing a reversibly activatable cell-penetrating peptide for tumor-specific cytoplasm targeting[J]. J Control Release, 2018, 279:147-156.
[14] Zaro JL, Fei L, Shen WC. Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery[J]. J Control Release, 2012, 158:357-361.
[15] Fei L, Yap LP, Conti PS, et al. Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide[J]. Biomaterials, 2014, 35:4082-4087.
[16] Sun C, Shen WC, Tu J, et al. Interaction between cell-penetrating peptides and acid-sensitive anionic oligopeptides as a model for the design of targeted drug carriers[J]. Mol Pharm, 2014, 11:1583-1590.
[17] Yu Y, Zu C, He D, et al. pH-dependent reversibly activatable cell-penetrating peptides improve the antitumor effect of artemisinin-loaded liposomes[J]. J Colloid Interface Sci, 2021, 586:391-403.
[18] Yeh TH, Chen YR, Chen SY, et al. Selective intracellular delivery of recombinant arginine deiminase (ADI) using pH-sensitive cell penetrating peptides to overcome ADI resistance in hypoxic breast cancer cells[J]. Mol Pharm, 2016, 13:262-271.
[19] Ouahab A, Cheraga N, Onoja V, et al. Novel pH-sensitive charge-reversal cell penetrating peptide conjugated PEG-PLA micelles for docetaxel delivery:in vitro study[J]. Int J Pharm, 2014, 466:233-245.
[20] Tian Y, Mi G, Chen Q, et al. Acid-induced activated cell-penetrating peptide-modified cholesterol-conjugated polyoxyethylene sorbitol oleate mixed micelles for pH-triggered drug release and efficient brain tumor targeting based on a charge reversal mechanism[J]. ACS Appl Mater Interfaces, 2018, 10:43411-43428.
[21] Liang J, Yang B, Zhou X, et al. Stimuli-responsive drug delivery systems for head and neck cancer therapy[J]. Drug Deliv, 2021, 28:272-284.
[22] Kesharwani SS, Kaur S, Tummala H, et al. Overcoming multiple drug resistance in cancer using polymeric micelles[J]. Expert Opin Drug Deliv, 2018, 15:1127-1142.
[23] Lee ES, Shin HJ, Na K, et al. Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization[J]. J Control Release, 2003, 90:363-374.
[24] Yin H, Lee ES, Kim D, et al. Physicochemical characteristics of pH-sensitive poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) mixed micelles[J]. J Control Release, 2008, 126:130-138.
[25] Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery[J]. Biomaterials, 2013, 34:1213-1222.
[26] Mu S, Liu Y, Wang T, et al. Unsaturated nitrogen-rich polymer poly(L-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release[J]. Acta Biomater, 2017, 63:150-162.
[27] Wang Z, Zhi K, Ding Z, et al. Emergence in protein derived nanomedicine as anticancer therapeutics:more than a tour de force[J]. Semin Cancer Biol, 2021, 69:77-90.
[28] Lee SY, Park HS, Lee KY, et al. Paclitaxel-loaded polymeric micelle (230 mg·m2) and cisplatin (60 mg·m2) vs paclitaxel (175 mg·m2) and cisplatin (60 mg·m2) in advanced non-small-cell lung cancer:a multicenter randomized phase ⅡB trial[J]. Clin Lung Cancer, 2013, 14:275-282.
[29] Wang HX, Zuo ZQ, Du JZ, et al. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines[J]. Nano Today, 2016, 11:133-144.
[30] Li F, Wang Y, Chen WL, et al. Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment[J]. Theranostics, 2019, 9:5886-5898.
[31] Swetha KL, Maravajjala KS, Sharma S, et al. Development of a tumor extracellular pH-responsive nanocarrier by terminal histidine conjugation in a star shaped poly(lactic-co-glycolic acid)[J]. Eur Polym J, 2021, 147:110337.
[32] Jia WF, Wang YS, Liu R, et al. Shape transformable strategies for drug delivery[J]. Adv Func Mater, 2021, 31:2009765.
[33] Yang PP, Luo Q, Qi GB, et al. Host materials transformable in tumor microenvironment for homing theranostics[J]. Adv Mater, 2017, 29:1605869.
[34] Zhang M, Guo X, Wang M, et al. Tumor microenvironment-induced structure changing drug/gene delivery system for overcoming delivery-associated challenges[J]. J Control Release, 2020, 323:203-224.
[35] He J, Xu S, Mixson AJ. The multifaceted histidine-based carriers for nucleic acid delivery:advances and challenges[J]. Pharmaceutics, 2020, 12:774.
[36] Gao Y, Jia L, Wang Q, et al. pH/redox dual-responsive polyplex with effective endosomal escape for codelivery of siRNA and doxorubicin against drug-resistant cancer cells[J]. ACS Appl Mater Interfaces, 2019, 11:16296-16310.
[37] Dhanya GR, Caroline DS, Rekha MR, et al. Histidine and arginine conjugated starch-PEI and its corresponding gold nanoparticles for gene delivery[J]. Int J Biol Macromol, 2018, 120:999-1008.
[38] He H, Du L, Guo H, et al. Redox responsive metal organic framework nanoparticles induces ferroptosis for cancer therapy[J]. Small, 2020, 16:e2001251.
[39] Huang W, Hao P, Qin J, et al. Hexahistidine-metal assemblies:a promising drug delivery system[J]. Acta Biomater, 2019, 90:441-452.
[40] Tang Q, Zhao D, Zhou Q, et al. Polyhistidine-based metal coordination hydrogels with physiologically relevant pH responsiveness and enhanced stability through a novel synthesis[J]. Macromol Rapid Commun, 2018, 39:e1800109.
[41] Li Y, Li AC, Xu Q. Intracellular delivery of his-tagged genome-editing proteins enabled by nitrilotriacetic acid-containing lipidoid nanoparticles[J]. Adv Healthc Mater, 2019, 8:e1800996.
[42] Ma D, Chen Y, Fang L, et al. Purification and characterization of RGD tumor-homing peptide conjugated human tumor necrosis factor alpha over-expressed in Escherichia coli[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 857:231-239.
[43] Wang M, Zhang L, Cai Y, et al. Bioengineered human serum albumin fusion protein as target/enzyme/pH three-stage propulsive drug vehicle for tumor therapy[J]. ACS Nano, 2020, 14:17405-17418.
[44] Liu R, He B, Li D, et al. Effects of pH-sensitive chain length on release of doxorubicin from mPEG-b-PH-b-PLLA nanoparticles[J]. Int J Nanomedicine, 2012, 7:4433-4446.
[45] Zhang X, Chen D, Ba S, et al. Poly(L-histidine) based triblock copolymers:pH induced reassembly of copolymer micelles and mechanism underlying endolysosomal escape for intracellular delivery[J]. Biomacromolecules, 2014, 15:4032-4045.
[46] Liu R, Li D, He B, et al. Anti-tumor drug delivery of pH-sensitive poly(ethylene glycol)-poly(L-histidine-)-poly(L-lactide) nanoparticles[J]. J Control Release, 2011, 152:49-56.
[47] Lee ES, Oh KT, Kim D, et al. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)[J]. J Control Release, 2007, 123:19-26.
[48] Zhang J, Zhang M, Ji J, et al. Glycyrrhetinic acid-mediated polymeric drug delivery targeting the acidic microenvironment of hepatocellular carcinoma[J]. Pharm Res, 2015, 32:3376-3390.
[49] Hong W, Chen D, Jia L, et al. Thermo- and pH-responsive copolymers based on PLGA-PEG-PLGA and poly(L-histidine):synthesis and in vitro characterization of copolymer micelles[J]. Acta Biomater, 2014, 10:1259-1271.
[50] Zhou Z, Badkas A, Stevenson M, et al. Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery[J]. Int J Pharm, 2015, 487:81-90.
[51] Zhang X, Chen D, Ba S, et al. Poly(L-histidine) based copolymers:effect of the chemically substituted L-histidine on the physio-chemical properties of the micelles and in vivo biodistribution[J]. Colloids Surf B Biointerfaces, 2016, 140:176-184.
[52] Johnson RP, Uthaman S, John JV, et al. Poly(PEGA)-b-poly(L-lysine)-b-poly(L-histidine) hybrid vesicles for tumoral pH-triggered intracellular delivery of doxorubicin hydrochloride[J]. ACS Appl Mater Interfaces, 2015, 7:21770-21779.
[53] Kim D, Lee ES, Park K, et al. Doxorubicin loaded pH-sensitive micelle:antitumoral efficacy against ovarian A2780/DOXR tumor[J]. Pharm Res, 2008, 25:2074-2082.
[54] Chen Q, Long M, Qiu L, et al. Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin[J]. Int J Nanomedinine, 2016, 11:5415-5427.
[55] Gao W, Ye G, Duan X, et al. Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer[J]. Int J Nanomedinine, 2017, 12:1047-1064.
[56] Qiu L, Qiao M, Chen Q, et al. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin[J]. Biomaterials, 2014, 35:9877-9887.
[57] Liu Y, Feng L, Liu T, et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer[J]. Nanoscale, 2014, 6:3231-3242.
[58] Li Z, Chen Q, Qi Y, et al. Rational design of multifunctional polymeric nanoparticles based on poly(L-histidine) and D-α-vitamin E succinate for reversing tumor multidrug resistance[J]. Biomacromolecules, 2018, 19:2595-2609.
[59] Hwang JH, Choi CW, Kim HW, et al. Dextran-b-poly(L-histidine) copolymer nanoparticles for pH-responsive drug delivery to tumor cells[J]. Int J Nanomedicine, 2013, 8:3197-3207.
[60] Qiu L, Li Z, Qiao M, et al. Self-assembled pH-responsive hyaluronic acid-g-poly(L-histidine) copolymer micelles for targeted intracellular delivery of doxorubicin[J]. Acta Biomater, 2014, 10:2024-2035.
[61] Li Z, Qiu L, Chen Q, et al. pH-sensitive nanoparticles of poly(L-histidine)-poly(lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery[J]. Acta Biomater, 2015, 11:137-150.
[62] Abbasi S, Yousefi G, AMJC Tamaddon, et al. Polyacrylamide-b-copolypeptide hybrid copolymer as pH-responsive carrier for delivery of paclitaxel:effects of copolymer composition on nanomicelles properties, loading efficiency and hemocompatibility[J]. Colloids Surf A, 2018, 537:217-226.
[63] Sun Y, Li Y, Nan S, et al. Synthesis and characterization of pH-sensitive poly(itaconic acid)-poly(ethylene glycol)-folate-poly(L-histidine) micelles for enhancing tumor therapy and tunable drug release[J]. J Colloid Interface Sci, 2015, 458:119-129.
[64] Johnson RP, Chung CW, Jeong YI, et al. Poly(L-histidine)-tagged 5-aminolevulinic acid prodrugs:new photosensitizing precursors of protoporphyrin IX for photodynamic colon cancer therapy[J]. Int J Nanomedicine, 2012, 7:2497-2512.
[65] Johnson RP, Jeong YI, John JV, et al. Lipo-poly(L-histidine) hybrid materials with pH-sensitivity, intracellular delivery efficiency, and intrinsic targetability to cancer cells[J]. Macromol Rapid Commun, 2014, 35:888-894.
[66] Herranz-Blanco B, Shahbazi MA, Correia AR, et al. pH-switch nanoprecipitation of polymeric nanoparticles for multimodal cancer targeting and intracellular triggered delivery of doxorubicin[J]. Adv Healthc Mater, 2016, 5:1904-1916.
[67] Shi M, Zhang J, Huang Z, et al. Stimuli-responsive release and efficient siRNA delivery in non-small cell lung cancer by a poly(L-histidine)-based multifunctional nanoplatform[J]. J Mater Chem B, 2020, 8:1616-1628.
[68] Hwang HS, Hu J, Na K, et al. Role of polymeric endosomolytic agents in gene transfection:a comparative study of poly(L-lysine) grafted with monomeric L-histidine analogue and poly(L-histidine)[J]. Biomacromolecules, 2014, 15:3577-3586.
[69] Liu Y, Qiao L, Zhang S, et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy[J]. Acta Biomater, 2018, 66:310-324.
[70] Jiang Y, Guo Z, Fang J, et al. A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer[J]. Mater Sci Eng C, 2020, 107:110224.
[71] Liu X, Fan Z, Zhang L, et al. Bcl-2 inhibitor uploaded upconversion nanophotosensitizers to overcome the photodynamic therapy resistance of cancer through adjuvant intervention strategy[J]. Biomaterials, 2017, 144:73-83.
[72] Ding J, Zhou Y, Li J, et al. Screening of HER2 overexpressed breast cancer subtype in vivo by the validation of high-performance, long-term, and noninvasive fluorescence tracer[J]. Anal Chem, 2015, 87:12290-12297.
[73] Bilalis P, Skoulas D, Karatzas A, et al. Self-healing pH- and enzyme stimuli-responsive hydrogels for targeted delivery of gemcitabine to treat pancreatic cancer[J]. Biomacromolecules, 2018, 19:3840-3852.
1.卢安, 王向宇, 闫仪, 王坚成*.肿瘤微环境响应型的RNA药物递送系统的研究进展[J]. 药学学报, 2022,57(1): 109-121
2.郑蓉蓉, 赵林平, 陈华清, 李仕颖, 余细勇.肿瘤微环境响应的仿生金属纳米粒用于光动力学治疗的研究[J]. 药学学报, 2020,55(7): 1672-1679
3.范博, 金明姬, 黄伟, 王启明, 高钟镐.细胞穿膜肽在药物递送系统中的研究进展[J]. 药学学报, 2016,51(2): 264-271